About Elagolix Sodium API
Therapeutic CategoryPain Management
CAS Number
832720-36-2
API Technology
High Potent
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF
Mechanism of Action
ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
Indication
ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis.
Related APIs
Elagolix Sodium
Pain Management
Ketorolac Tromethamine
Pain Management
Naproxen
Pain Management
Naproxen Sodium
Pain Management
Naratriptan Hydrochloride
Pain Management
Sumatriptan Succinate
Pain Management
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
Do not take elagolix if you are pregnant or think you are pregnant.
-
Store at room temperature (25°C). Excursion alloweed between 15 - 30°C
-
Elagolix is used to manage pain due to endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes infertility, pain before and during menstrual periods, pain during and after sexual activity, and heavy or irregular bleeding)
-
Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin. These could be symptoms of a serious liver problem.
-
We offer Amorphous form of Elagolix sodium API
-
Elagolix is available in tablet dosage form with 150 and 200 mg
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.